- The company is constructing the first-ever cannabis mall, offering products manufactured in-house and serving outside vendors
- GCGX is reaching into the Lake Tahoe, California-area to provide products to more than 30 million who have limited or no access to recreational dispensaries
- The company is adding a medical grade nutraceutical division
- GCGX aims to commence the registration process for listing on the Nasdaq, with a target date of mid- to late-June
Headquartered in Florida, Global Consortium Inc. (OTC: GCGX) is a diversified, cannabis-holding company expanding its reach nationwide. The company’s portfolio includes several subsidiaries, partnerships and licensing agreements. Focused on sustainable revenues from operations, GCGX’s approach is seed to shelf, thereby providing the company with optimal control of the end-consumer experience. The company believes that the first to market will dominate and is pushing its way to the forefront.
The company is currently constructing the first-ever cannabis mall. Located in Sacramento, California, this 64,000-square-foot building will follow GCGX products from seed to sale. Manufacturing, distribution, delivery, retail, testing and cultivation operations are all expected to take place under the same roof. Once completed, the cannabis mall will be home to the largest operational CBD and THC distillate and edible manufacturing facility in the country. The mall will offer products manufactured in house, as well as serving outside cannabis vendors.
GCGX is reaching into the Lake Tahoe, Nevada, area to establish itself as one of the first in the recreational space. The area has no recreational dispensaries, and the more than 30 million people who live and visit Lake Tahoe rely on a single licensed delivery company. All of Global Consortium’s products are now available in the area, and the weekly order placed is worth a minimum of $50,000.
The Global Consortium product line currently consists of Infused Oils and Infused Edibles. The company’s Infused Oils line creates natural, pesticide-free, medicinal cannabis extracts that are strain-specific THC and CBD oils of premium quality. In its 13 years of production, the company’s Infused Edibles line has received 17 first-place awards for its U.S.-grown and CBD-infused products and currently serves an estimated 400 stores in 15 states. The production of all edibles is expected to relocate by the end of Q2 2019 to the new cannabis mall (http://ibn.fm/54BSn).
The company also recently announced (http://ibn.fm/6zZsa) that it is adding a medical grade nutraceutical division. Products produced from this division will be overseen by medical doctors and veterinarians, and they may include lotions, balms, ointments, liquids, pills and powders. While some products will be made available to the public, others will be white labeled for customization to providing doctors’ practices.
During a recent investor conference call (http://ibn.fm/pVmEu), GCGX CEO Matthew Dwyer also emphasized the company’s goal to begin the registration process for being listed and traded on the Nasdaq by mid- to late-June.
For more information, visit the company’s website at www.GCGX.org
NOTE TO INVESTORS: The latest news and updates relating to GCGX are available in the company’s newsroom at http://ibn.fm/GCGX